Table 2.
Ongoing trials targeting the EGFR in glioblastoma (GBM).
| Drug | GBM | Phase | Characteristics | NCT No. |
|---|---|---|---|---|
| Small-Molecule Kinase Inhibitors and/or Combination with Other Therapy | ||||
| GC1118 | R | II | Focuses on overall response rate and exploration of predictive/prognostic biomarkers | NCT03618667 |
| Osimertinib Fludeoxyglucose F-18 (FDG) | R | II | Studied the intra-patient variability of tumor FDG uptake, which was determined using double baseline FDG PET prior to osimertinib exposure | NCT03732352 |
| EGFR BATs with SOC RT and TMZ | R | I | Immune measures in blood anti-GBM cytotoxicity of peripheral blood mononuclear cells directed at GBM cell lines | NCT03344250 |
| Dacomitinib | C | II | Progression-free survival (PFS) at six months (PFS6m) and Safety and tolerability of oral administration of PF-00299804. | NCT01520870 |
| Temozolomide, ABT-414, Radiation | A, NR | II III |
Overall Survival (OS) | NCT02573324 |
| EGFR(V)-EDV-Dox | R | I | Overall Survival (OS) and identification of recommended phase 2 dose of EGFR(V)-EDV-Dox in subjects with recurrent GBM | NCT02766699 |
| C225-ILs-dox | R | I | Tumor response achieved in the treatment phase was assessed as per RANO criteria | NCT03603379 |
| Protein expression analysis | C | - | Overall survival and the free survival was predicted based on the molecular characteristics | NCT00897663 |
| EGFRvIII-CARs | R | I | Assessment of T cell trafficking within the brain tumor | NCT03283631 |
| EGFRBi Armed Autologous T Cells | W | I II |
Overall survival, change of cytokine profile, incident toxicity, and the overall survival was assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 | NCT02521090 |
| Erlotinib hydrochloride | T | II | Disease response measured objectively by MRI of brain duration of progression-free survival (PFS) | NCT00387894 |
| Radiation, temozolomide depatuxizumab mafodotin | A, NR | III | Cumulative dose of depatuxizumab mafodotin | NCT03419403 |
| Gefitinib + Radiation therapy | C | I II |
Overall survival by EGFR status | NCT00052208 |
| Cetuximab, Mannitol | R | I II |
Composite overall response rate was assessed through RANO | NCT02861898 |
| AMG 596 | R | I | Number of subject with treatment-emergent adverse events | NCT03296696 |
| AMG 596 | C | I | Overall survival and anti-AMG 595 antibody formation | NCT01475006 |
| PI3K/ART/mTOR | ||||
| PX-866 | C | II | Measurement of progression and response of brain tumor using MRI or CT scan | NCT01259869 |
| INC280 | T | I, II | Number of Patients Reporting Dose Limiting Toxicities (DLTs) in Phase 1 and Phase II Surgical Arm: Concentrations of INC280 and Buparlisib in Tumor | NCT01870726 |
| XL765 (SAR 245409) + XL147 (SAR 245408) | C | I | To assess the biological effect and PI3K/mTOR modulations of XL 765 and XL 147 in GBM tissue | NCT01240460 |
| BKM120 + Surgery | C | II | BKM120 brain plasma ratio at time of surgery | NCT01339052 |
| MK-3475 + PI3K/AKT Inhibitors | # | I, II | Progression-free survival | NCT02430363 |
| GDC-0084 + Radio Therapy | R | I | To estimate the maximum tolerated dose (MTD) or RP2D of GDC-0084 after radiation therapy (RT) | NCT03696355 |
| AZD2014 | A, NR | I | Recommended phase II dose (RP2D) of AZD2014 | NCT02619864 |
| GDC-0084 | R | II | Dose-limiting toxicities (DLTs) | NCT03522298 |
| AZD8055 | C | I | Establishment of MTD of AZD8055 with recurrent gliomas | NCT01316809 |
| GDC-0084 + Radiation Therapy | R | I | To estimate the MTD or RP2D of GDC-0084 after RT | NCT03696355 |
| CC-115 | A, NR | I | To determine the MTD, Non-tolerated dose and Dose-Limiting Toxicity | NCT01353625 |
R—Recruiting, C—Completed, A—Active, NR—Not Recruiting, T—Terminated, W—Withdrawn, and #—Study has passed its completion date and status has not been verified in more than two years.